Severity Assessment, Patient Selection, and Comparison of Treatment Options for CRSwNP: Are We Ready to Set our Sights on a Standard? – Virtual

Join us online to learn more about biologics for CRSwNP!

Sunday, October 1, 2023
8:00 AM – 9:00 AM CDT


This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., and Sanofi.

This commercially supported Product Theater is independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and is not accredited by AAOA.


Chronic rhinosinusitis (CRS) is among the most prevalent and expensive chronic disorders in the US. According to the Centers for Disease Control and Prevention, 28.9 million adults (11.6%) have CRS, and at least one economic analysis ranks the disease among the top 10 most costly conditions. Among patients with CRS, an estimated 25%–30% have concurrent nasal polyps (CRSwNP). CRSwNP is most commonly observed in patients between 40 and 60 years of age, and while polyps are more common in men, women are more likely to have severe disease, comorbid asthma, and aspirin-exacerbated respiratory disease. Compared to their counterparts without polyps (CRSsNP), patients with CRSwNP carry a much higher disease burden, greater risk for comorbidities, the need for functional endoscopic sinus surgery (ESS), repeat revision surgeries, and dependence on oral corticosteroids (OCS).

Join us virtually on the Whova conference platform. This program will improve patient care through improved ability to assess disease severity and burden, selection of patients for surgical or biologic treatment options, and evidence on comparative safety and efficacy and real-world data of available treatments for CRSwNP.


This activity addresses the needs of otolaryngic allergists, physicians, physician assistants, and nurse practitioners involved in the management of patients with CRSwNP.


Upon completion of this educational activity, participants should be able to:

  • Apply evidence-based guidance to assess the severity and QOL impact of CRSwNP
  • Evaluate clinical trial data on the efficacy and safety of biologics and surgical options for patients with CRSwNP
  • Incorporate current guidelines and expert recommendations into the positioning of biologic therapy, sinus surgery, and OCS for the treatment of patients with CRSwNP


Anju T. Peters, MD
Professor of Medicine
Director of Clinical Research
Division of Allergy/Immunology and Otolaryngology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Stella Lee, MD
Section Chief Rhinology
Brigham and Women’s Hospital
Harvard Medical School
Weston, Massachusetts

Michael Platt, MD, MSc
Associate Professor and Residency Director
Director of Rhinology and Endoscopic Skull Base Surgery
Department of Otolaryngology- Head and Neck Surgery
Chobanian and Avedesian School of Medicine
Boston University
Boston, Massachusetts


Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Stella Lee, MD
Advisory Board: AstraZeneca, Genentech, GSK, Lyra Therapeutics, OptiNose, Sanofi Regeneron

Anju Peters, MD
Advisory Board: AstraZeneca, GSK, Merck, Sanofi Regeneron
Consulting: OptiNose
Research: AstraZeneca, Merck, Sanofi Regeneron

Michael Platt, MD, MSc
Consulting: GI Reviewers, LLC. Independent reader for CRS biologics studies

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Sunday, October 1, 2023
8:00 AM – 9:00 AM CDT

8:00 AM – 8:25 AM CDT Scientific Presentation

  • Disease burden of CRSwNP
  • Assessment of disease severity and QoL impact
  • Current Treatment landscape
  • Treatment selection
8:25 AM – 8:50 AM CDT Interactive Poster Session

  • Station #1: Assessment of disease severity and QoL impact
  • Station #2: Comparative evidence
  • Station #3: Guidelines and expert recommendations
8:50 AM – 9:00 AM CDT Question & Answer Session


There are no fees for participating and receiving CME credit for this activity. For your participation, you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME Credit. To do so, you must participate in the live program and complete the posttest and evaluation following the event. A statement of credit will be issues within 3 weeks of receipt of a completed activity evaluation form.